|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 258.50 EUR | +0.74% |
|
+3.52% | +8.34% |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
| 06-22 | UBS Trims UCB's PT, Affirms Buy Rating | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 274.9 | 285.4 | 279.5 |
| Spread/Res. | -5.97% | -9.43% | -7.51% |
| Spread/Supp. | +14.28% | +14.28% | +40.11% |
| Support | 226.2 | 226.2 | 184.5 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
Select your edition
All financial news and data tailored to specific country editions
